NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 1 Sept 2026
- Closes
- 17 Apr 2029, 23:59 UTC
- Reference
- PAR-27-051
- Location
- United States
- Sector
- Healthcare & Pharma
Details
The National Institutes of Health seek to advance their mission by providing the scientific community with the opportunity to request access to biospecimens from the Adolescent Brain Cognitive DevelopmentSM (ABCD) Study, the HEALthy Brain and Child Development (HBCD) Study, and the Population Assessment of Tobacco and Health (PATH) Study to conduct research consistent with the respective study objectives that will maximize the scientific utility of these limited samples. Applications should expand the knowledge gained from these studies and advance our understanding of the multiple genetic and environmental factors, such as exposure to substances, that affect health and disease over the course of a lifetime. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
CFDA number(s): 93.121
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 398 open Healthcare & Pharma tenders in United States. This one closes in 936 days.
More from this buyer
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)· closes 16 Jul
- Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)· closes 25 May
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)· closes 10 Nov
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)· closes 10 Nov
Similar Healthcare & Pharma tenders
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
- Development of innovative antimicrobials against pathogens resistant to antimicrobials· closes 13 Apr
- Development of monoclonal antibodies to prevent and treat infections from Flaviviruses· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Provision of Private Hospital Capacity to support Urgent and Emergency CareHealth Service Executive (HSE) · Ireland
- Panel for Counselling and Psychotherapy ServicesUniversity College Dublin ( UCD ) · Ireland
- HSE 28439 - Restricted Procedure to procure a HSE Enterprise Integration Platform as a Service ( EiPaaS)Health Service Executive (HSE) · Ireland
- Provision of Occupational Health ServicesUisce Éireann · Ireland
- Supply of Accessibility Ramps, Wheelchair lifts, Parts and Servicing, Maintenance and TrainingBus Eireann/Irish Bus · Ireland
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →